Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to study the ability of a radioactive drug called
"Technetium Glucarate" to detect whether the cause of chest pain in patients entering the
emergency department with no obvious signs of heart attack is due to a condition called Acute
Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the
patient will undergo an imaging procedure to detect if the drug has accumulated in the heart.
Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.
Phase:
Phase 2
Details
Lead Sponsor:
Molecular Targeting Technologies, Inc.
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) University Hospitals Cleveland Medical Center University of Alabama at Birmingham University of Pittsburgh Yale University